EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis

Ziwei Hu, Shaozhe Cai, Yikai Yu, Yu Chen, Bei Wang, Di Wang, Rui Zeng, Xiaofeng He, Guifen Shen, Fei Yu, Zhipeng Zeng, Yuxue Chen und 11 weitere

Annals of the Rheumatic Diseases · 2025-10 · 84 (10) · 1675-1683

DOI: 10.1016/j.ard.2025.06.2128 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of the Rheumatic Diseases, 2025-10. Verfasst von Ziwei Hu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, Chin…. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Immunotherapy, Adoptive, Lupus Nephritis, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tongji Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to evaluate the safety and efficacy of anti-B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells in treating refractory lupus nephritis (LN). METHODS: This is an open-label, single-arm clinical trial assessing anti-BCMA CAR T cells in treating refractory LN patients. CAR T cells were infused following lymphodepletion therapy with cyclophosphamide and fludarabine. Patients were regularly followed up, in which clinical assessments were performed and laboratory indices were collected. Repeated renal biopsies and single cell RNA sequencing in certain patients were performed to help evaluate the therapeutic efficacy. The primary endpoints were the safe dosage of single infusion and the occurrence of adverse events, while the secondary endpoints focused on the therapeutic efficacy (eg, changes of Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2000]). RESULTS: Seven biopsy-confirmed LN patients were enrolled in this study with a median follow-up of 9 months, whose peripheral B cells were effectively eliminated within the first month postinfusions and restored within 3 months except one patient. Hypogammaglobulinemia was frequently observed in this study. Only one case of grade 1 cytokine release syndrome was noted, and no immune effector cell-associated neurotoxicity syndrome or severe infection was reported. SLEDAI-2K scores decreased from a median of 18 (range 10-22) at baseline to 0 (range 0-4) at the last follow-up, and 5 out of 7 patients achieved definition of remission in systemic lupus erythematosus (DORIS) complete remission. Decreased deposition of immune complex, reduced clonal abundance, and alleviated proinflammatory status of peripheral lymphocytes were also observed in repeated renal biopsy and transcriptomic analyses,. CONCLUSIONS: Anti-BCMA CAR T therapy can help LN patients inducing and maintaining disease remission status safely and effectively, which indicated the potential feasibility of the BCMA-only-targeting strategy in treating autoimmune diseases with abnormal humoral immune responses through CAR products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-Cell Maturation AntigenImmunotherapy, AdoptiveLupus NephritisReceptors, Chimeric AntigenAdultFemaleHumansMaleMiddle AgedYoung AdultB-LymphocytesCyclophosphamideImmunosuppressive AgentsRemission InductionTreatment OutcomeVidarabine

Substanzen

B-Cell Maturation AntigenCyclophosphamidefludarabineImmunosuppressive AgentsReceptors, Chimeric AntigenVidarabine

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Shenzhen Pregene Biopharma Company Ltd., Shenzhen, China. Electronic address: zhangjs@pregene.com.
  • Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: yecong@tjh.tjmu.edu.cn.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: cunrui5650@hust.edu.cn.

Förderung

  • Tongji Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Hu, Z., Cai, S., Yu, Y., Chen, Y., Wang, B., Wang, D., Zeng, R., He, X., Shen, G., Yu, F., Zeng, Z., Chen, Y., Luo, X., Zhang, Z., Zhang, P., Xiong, H., Bai, L., Ye, P., Lin, S., …, & Dong, L. (2025). BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Annals of the Rheumatic Diseases, 84(10), 1675-1683. https://doi.org/10.1016/j.ard.2025.06.2128

Vancouver

Hu Z, Cai S, Yu Y, Chen Y, Wang B, Wang D, et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Annals of the Rheumatic Diseases. 2025;84(10):1675-1683. doi:10.1016/j.ard.2025.06.2128

BibTeX
@article{Hu2025,
  author = {Hu, Ziwei and Cai, Shaozhe and Yu, Yikai and Chen, Yu and Wang, Bei and Wang, Di and Zeng, Rui and He, Xiaofeng and Shen, Guifen and Yu, Fei and Zeng, Zhipeng and Chen, Yuxue and Luo, Xiaofang and Zhang, Ziyun and Zhang, Peiling and Xiong, Hui and Bai, Lin and Ye, Ping and Lin, Shengyan and Zhang, Jishuai and Ye, Cong and Li, Chunrui and Dong, Lingli},
  title = {BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {10},
  pages = {1675--1683},
  doi = {10.1016/j.ard.2025.06.2128}
}
Kostenlos starten →